$SPRC News

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

SciSparc Subsidiary NeuroThera Labs Files Patent Application In Hong Kong For Novel Combination Treatment For Major Depressive Disorder, Developed In Collaboration With Clearmind Medicine

SciSparc Subsidiary NeuroThera Labs Files Patent Application In Hong Kong For Novel Combination Treatment For Major Depressive Disorder, Developed In Collaboration With Clearmind Medicine

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Neurothera Labs Inc. Announces Definitive Agreement to Acquire Majority Stake in Cliniquantum Ltd.

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

SciSparc announces 1-for-9 reverse share split

SciSparc Announces 1-For-9 Reverse Stock Split

Scisparc Files Prospectus For Offering $50M Securities

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance Such as MRSA

SciSparc Says NeuroThera Labs Granted U.S. Patent For Cannabinoid Technology To Overcome Antimicrobial Resistance. BZ NOTE: SciSparc Has 75% Controlling Interest In NeuroThera Labs

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

CORRECTION: SciSparc Acquires MUSE IP Portfolio From Xylo in Equity-Based Asset Deal; SciSparc Issued To Xylo An Amount Of Ordinary Shares Of The Company, Which Represents 19.99% Of The Issued And Outstanding Share Capital Of SciSparc